North America Anticoccidial Drugs Market Size (2024 - 2029)

North America Anticoccidial Drugs Market Analysis

The North America Anticoccidial Drugs Market size is estimated at USD 537.19 million in 2024, and is expected to reach USD 673.61 million by 2029, growing at a CAGR of 4.63% during the forecast period (2024-2029).

Anticoccidial drugs market is being driven by factors such as the rising incidence of coccidiosis in food-producing animals and companion animals, coupled with the rising awareness regarding animal health across the North America.

Also, advancements in veterinary healthcare are one of the major factors fueling the growth of the market studied across the world. For instance, in April 2019, Creative Diagnostics announced the launch of a series of innovative anticoccidial drug analysis products and services for its global clients.

Moreover, In August 2020, Merck Animal Health announced the acquisition of completion of its previously announced acquisition of the worldwide rights to VECOXAN which used for prevention of coccidiosis in calves and lambs, from Elanco Animal Health.

However, the use of alternative treatments, such as vaccines and herbal remedies, to treat Coccidiosis is likely to hamper the growth of anticoccidial drugs market across the world.

North America Anticoccidial Drugs Industry Segmentation

Coccidiosis is one of the most frequent and prevalent parasitic diseases among domesticated animals and its symptoms include weight loss, mild intermittent to severe diarrhoea, faeces containing mucus or blood, dehydration, and decreased breeding. Coccidiosis is caused by single-celled parasites (protozoa) called Eimeria, which undergo a simple life cycle in the gut. Any drug used to combat the progression of coccidiosis in birds or animals, both food-producing and non-food producing, is termed as an anticoccidial.